Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature

Edgardo S. Santos, Leopoldo Arosemena, Luis E. Raez, Christopher B O'Brien, Arie Regev

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Rituximab, a chimeric monoclonal anti-CD20 antibody, has shown activity in several autoimmune disorders. We describe a case of a 52 years old female who was diagnosed with idiopathic thrombocytopenic purpura and concomitant autoimmune hepatitis (AIH), both non-responsive to steroids. She was subsequently treated with rituximab, which resulted in a rapid increase in her platelet count and an unexpected normalization of her hepatic biochemical tests. Both her platelet count and her hepatic biochemical tests remained normal for over 5 months. In this case, rituximab showed an impressive clinical response for the treatment of AIH, and it may be considered as an alternative treatment in patients who do not respond to corticosteroid therapy. Prospective randomized studies in AIH are needed to validate this observation.

Original languageEnglish
Pages (from-to)625-629
Number of pages5
JournalLiver International
Volume26
Issue number5
DOIs
StatePublished - Jun 1 2006

Fingerprint

Autoimmune Hepatitis
Idiopathic Thrombocytopenic Purpura
Monoclonal Antibodies
Platelet Count
Liver
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Therapeutics
Steroids
Prospective Studies
Rituximab

Keywords

  • Autoimmune hepatitis
  • Idiopathic thrombocytopenic purpura
  • Monoclonal antibody
  • Rituximab

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{f5815284e7694c91b46736735e1caa97,
title = "Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature",
abstract = "Rituximab, a chimeric monoclonal anti-CD20 antibody, has shown activity in several autoimmune disorders. We describe a case of a 52 years old female who was diagnosed with idiopathic thrombocytopenic purpura and concomitant autoimmune hepatitis (AIH), both non-responsive to steroids. She was subsequently treated with rituximab, which resulted in a rapid increase in her platelet count and an unexpected normalization of her hepatic biochemical tests. Both her platelet count and her hepatic biochemical tests remained normal for over 5 months. In this case, rituximab showed an impressive clinical response for the treatment of AIH, and it may be considered as an alternative treatment in patients who do not respond to corticosteroid therapy. Prospective randomized studies in AIH are needed to validate this observation.",
keywords = "Autoimmune hepatitis, Idiopathic thrombocytopenic purpura, Monoclonal antibody, Rituximab",
author = "Santos, {Edgardo S.} and Leopoldo Arosemena and Raez, {Luis E.} and O'Brien, {Christopher B} and Arie Regev",
year = "2006",
month = "6",
day = "1",
doi = "10.1111/j.1478-3231.2006.01262.x",
language = "English",
volume = "26",
pages = "625--629",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab

T2 - Case report and review of literature

AU - Santos, Edgardo S.

AU - Arosemena, Leopoldo

AU - Raez, Luis E.

AU - O'Brien, Christopher B

AU - Regev, Arie

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Rituximab, a chimeric monoclonal anti-CD20 antibody, has shown activity in several autoimmune disorders. We describe a case of a 52 years old female who was diagnosed with idiopathic thrombocytopenic purpura and concomitant autoimmune hepatitis (AIH), both non-responsive to steroids. She was subsequently treated with rituximab, which resulted in a rapid increase in her platelet count and an unexpected normalization of her hepatic biochemical tests. Both her platelet count and her hepatic biochemical tests remained normal for over 5 months. In this case, rituximab showed an impressive clinical response for the treatment of AIH, and it may be considered as an alternative treatment in patients who do not respond to corticosteroid therapy. Prospective randomized studies in AIH are needed to validate this observation.

AB - Rituximab, a chimeric monoclonal anti-CD20 antibody, has shown activity in several autoimmune disorders. We describe a case of a 52 years old female who was diagnosed with idiopathic thrombocytopenic purpura and concomitant autoimmune hepatitis (AIH), both non-responsive to steroids. She was subsequently treated with rituximab, which resulted in a rapid increase in her platelet count and an unexpected normalization of her hepatic biochemical tests. Both her platelet count and her hepatic biochemical tests remained normal for over 5 months. In this case, rituximab showed an impressive clinical response for the treatment of AIH, and it may be considered as an alternative treatment in patients who do not respond to corticosteroid therapy. Prospective randomized studies in AIH are needed to validate this observation.

KW - Autoimmune hepatitis

KW - Idiopathic thrombocytopenic purpura

KW - Monoclonal antibody

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=33646809309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646809309&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2006.01262.x

DO - 10.1111/j.1478-3231.2006.01262.x

M3 - Article

C2 - 16762009

AN - SCOPUS:33646809309

VL - 26

SP - 625

EP - 629

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -